VEGF-A splicing variant in plasma is a predictive potential biomarker of bevacizumab in advanced non-squamous non-small cell lung cancer
{{output}}
Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor-A (VEGF-A), a key mediator of tumor angiogenesis. Among VEGF-A splice variants, VEGF-Axxxa has proangiogenic activity, whereas VEGF-Axxxb exerts anti-angiogenic effects. Recent m... ...
